Anavex Life Sciences (AVXL) Cash from Investing Activities (2013 - 2014)

Anavex Life Sciences (AVXL) reported Cash from Investing Activities of -$688.0 for Q3 2014, up 70.43% sequentially from -$2327.0 in Q4 2013.

Anavex Life Sciences (AVXL) Cash from Investing Activities (2013 - 2014) Analysis & Trends

Anavex Life Sciences (AVXL) has 2 years of Cash from Investing Activities data on file, last reported at -$688.0 in Q3 2014.

For the quarter ending Q3 2014, Cash from Investing Activities changed N/A year-over-year to -$688.0; the trailing twelve-month figure through Jun 2015 stood at -$688.0 (up 70.43% YoY), and the FY2014 full-year result was -$3015.0, changed N/A from the prior year.
Cash from Investing Activities climbed to -$688.0 in Q3 2014, from -$2327.0 in the prior quarter.
In the past five years, Cash from Investing Activities ranged from a high of -$688.0 in Q3 2014 to a low of -$2327.0 in Q4 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Investing Activities (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	-45.51 Mn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-431.90 Mn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	-428.90 Mn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	172.62 Mn
10	Anavex Life Sciences	223.91 Mn	92.16 Mn	-	-

Download Data